Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis.
We reported the comparative effectiveness of adalimumab and golimumab in ulcerative colitis.
118 patients treated with adalimumab and 79 treated with golimumab were included and evaluated at 8 weeks and at the end of follow up.
Overall clinical benefit was 72.6% at 8 weeks and 58.9% at the end of follow up. Patients with longer disease duration and those treated with adalimumab had a better outcome. Clinical benefit was 78.8% in adalimumab patients and 63.3% in golimumab patients (p = 0.026) after 8 weeks; it was 66.9% in adalimumab patients and 46.8% in golimumab patients (p = 0.008) at the end of follow up. These data were confirmed by propensity score analysis. A further analysis considering adalimumab optimization as treatment failure showed that the difference between adalimumab and golimumab was not significant.
Adalimumab and golimumab are effective in the treatment of ulcerative colitis. Adalimumab seems to be more effective than golimumab. This difference is probably affected by the impossibility of golimumab to be optimized in Italy while adalimumab is.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Digestive and Liver Disease
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Inflammatory bowel disease: cause and immunobiology.Lancet. 2007; 369: 1627-–1640
- The role of TNFα in ulcerative colitis.J Clin Pharmacol. 2007; 47: 930-941
- The biologics of ulcerative colitis.Expert Opin Biol Ther. 2017; 17: 175-184
- Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: meta-analysis of placebo-controlled trials.Dig Liver Dis. 2015; 47: 356-364
- Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.Ann Intern Med. 2014; 160: 704-711
- Infliximab is superior to other biological agents for treatment of active ulcerative colitis: a metaanalysis.World J Gastroenterol. 2015; 21: 6044-6051
- Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.Expert Rev Gastroenterol Hepatol. 2015; 9: 693-700
- Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis.Aliment Pharmacol Ther. 2014; 39: 660-671
- Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis.Aliment Pharmacol Ther. 2016; 44: 310-311
- European Crohn’s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management.J Crohns Colitis. 2017; : 769-784
- An introduction to propensity score methods for reducing the effects of confounding in observational studies.Multivar Behav Res. 2011; 46: 399-424
- Constructing inverse probability weights for marginal structural models.Am J Epidemiol. 2008; 168: 656-664
- Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.Stat Med. 2015; 34: 3661-3679
- Comparing propensity score methods in balancing covariates and recovering impact in small sample educational program evaluations.Pract Assess Res Eval. 2013; 18
- The performance of different propensity score methods forestimating marginal hazard ratios.Stat Med. 2013; 32: 2837-–2849
- R: a language and environment for statistical computing.R Foundation for Statistical Computing, Vienna, Austria2016
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.Gut. 2011; 60: 780-787
- Subcutaneous golimumab induces clinicalresponse and remission in patients with moderate-to-severe ulcerative colitis.Gastroenterology. 2014; 146: 85-95
- Adalimumab induces and maintains clinicalremission in patients with moderate-to-severe ulcerative colitis.Gastroenterology. 2012; 142: 257-265
- Subcutaneous golimumab maintains clinicalresponse in patients with moderate-to-severe ulcerative colitis.Gastroenterology. 2014; 146: 96-109
- Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naéve and non-naéve patients.J Gastroenterol. 2017; 52: 788-–799
- Clinical outcomes of golimumab as first, second or third anti-tnf agent in patients with moderate-to-severe ulcerative colitis.Inflamm Bowel Dis. 2017; 23: 1394-1402
- The importance of considering differences in study design in network meta-analysis: an application using anti-tumor necrosis factor drugs for ulcerative colitis.Med Decis Making. 2017; 37: 894-904
Published online: June 21, 2018
Accepted: June 13, 2018
Received in revised form: May 27, 2018
Received: February 10, 2018
© 2018 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.